Solid Tumour

ACTengine® IMA203/​IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/​or Refractory Solid Tumors (ACTengine) – NCT03686124

This Phase 1 clinical trial is investigating a personalised T-cell therapy called IMA203 (also known as anzutresgene autoleucel) for people with advanced solid tumours, including metastatic uveal melanoma. IMA203 is a type of immunotherapy designed to genetically modify a patient’s own immune cells (T cells) so they can better recognise and attack cancer cells carrying […]

ACTengine® IMA203/​IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/​or Refractory Solid Tumors (ACTengine) – NCT03686124 Read More »

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy – NCT04573881

This is a single-arm, non-randomized prospective trial designed to assess the effectiveness and safety of the HistoSonics System, a novel treatment for primary or metastatic liver tumors. The trial aims to evaluate how well the system works and its safety profile in targeting liver tumors.

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy – NCT04573881 Read More »

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801 alone and with Pembrolizumab – NCT04130516

This Phase 1/2, first-in-human, open-label, multicenter study aims to determine the safest and most effective dose (Maximum Tolerated Dose, MTD, or Recommended Phase 2 Dose, RP2D) of LNS8801, both on its own and in combination with pembrolizumab. Using a 3+3 dose escalation design, the study will evaluate the safety, tolerability, how the drug behaves in

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801 alone and with Pembrolizumab – NCT04130516 Read More »

Study of RP-3500, Camonsertib, in Advanced Solid Tumors – NCT04497116

This Phase 1/2a study, known as the TRESR Study, is investigating the safety, how the body processes and responds to the drug (pharmacokinetics and pharmacodynamics), and the early effectiveness of RP-3500 (camonsertib) in treating advanced solid tumours with specific genetic mutations. RP-3500 will be tested both on its own and in combination with talazoparib (a

Study of RP-3500, Camonsertib, in Advanced Solid Tumors – NCT04497116 Read More »

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) – Master Screening Protocol (DETERMINE) – NCT05722886

DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) – Master Screening Protocol (DETERMINE) – NCT05722886 Read More »